Promoting Life-Saving New Therapies for Neonates Act of 2017
Latest action · May 26, 2017 Referred to the Subcommittee on Health.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedMay 24, 2017
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Promoting Life-Saving New Therapies for Neonates Act of 2017
This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to award the sponsor of a new drug or biological product for the treatment of newborns a neonatal drug exclusivity voucher upon approval of the medication. A neonatal drug exclusivity voucher is a transferable voucher for a one-year extension of all existing patents and marketing exclusivities for a brand name medication. For a sponsor to be eligible for a voucher, the new medication must: (1) treat a condition identified in the Priority List of Critical Needs for Neonates required under this bill, and (2) have been studied in newborns.
A voucher may be revoked if the new medication is not marketed in the United States within one year of approval.
A voucher may not be used: (1) to extend the marketing exclusivity period for a drug for which the FDA requires an assessment of the safety and effectiveness in newborns, or (2) on the same product as a priority review voucher.
A sponsor intending to use a voucher must notify the FDA at least 15 months before the expiration of the patents or exclusivity to be extended.
The Government Accountability Office must study the effectiveness of this voucher program.Cosponsors 37
Members who signed on, in the order they did. Signatures ran from May 24, 2017 to Dec 18, 2017; 1 is an original cosponsor, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-NM | Ben Ray Luján | Original | May 24, 2017 |
| D-NJ | Bill Pascrell, Jr. | Jun 7, 2017 | |
| D-CA | Grace F. Napolitano | Jun 7, 2017 | |
| D-CA | John Garamendi | Jun 7, 2017 | |
| D-WA | Derek Kilmer | Jun 13, 2017 | |
| D-VA | Gerald E. Connolly | Jun 13, 2017 | |
| D-NY | Kathleen M. Rice | Jun 13, 2017 | |
| D-DE | Lisa Blunt Rochester | Jun 13, 2017 | |
| D-CA | Mark DeSaulnier | Jun 13, 2017 | |
| D-CA | Scott H. Peters | Jun 13, 2017 | |
| D-MA | Seth Moulton | Jun 13, 2017 | |
| D-CA | Tony Cárdenas | Jun 13, 2017 | |
| R-KY | Brett Guthrie | Jun 21, 2017 | |
| R-ME | Bruce Poliquin | Jun 21, 2017 | |
| R-NJ | Leonard Lance | Jun 21, 2017 | |
| R-KS | Lynn Jenkins | Jun 21, 2017 | |
| D-CA | Pete Aguilar | Jun 21, 2017 | |
| R-CO | Scott R. Tipton | Jul 13, 2017 | |
| R-WV | Alexander X. Mooney | Jul 25, 2017 | |
| R-MN | Erik Paulsen | Jul 25, 2017 | |
| R-FL | Gus M. Bilirakis | Jul 28, 2017 | |
| D-WI | Ron Kind | Jul 28, 2017 | |
| D-WI | Gwen Moore | Sep 5, 2017 | |
| R-MO | Jason Smith | Sep 5, 2017 | |
| D-NY | Sean Patrick Maloney | Sep 5, 2017 | |
| D-NJ | Donald Norcross | Sep 25, 2017 | |
| R-NC | Richard Hudson | Sep 25, 2017 | |
| D-TX | Marc A. Veasey | Sep 27, 2017 | |
| R-NJ | Rodney P. Frelinghuysen | Oct 3, 2017 | |
| R-IL | Peter J. Roskam | Oct 12, 2017 | |
| R-NY | Peter T. King | Oct 12, 2017 | |
| D-IL | Bobby L. Rush | Oct 24, 2017 | |
| D-NC | David E. Price | Oct 24, 2017 | |
| R-KS | Roger Marshall | Oct 31, 2017 | |
| D-CA | Anna G. Eshoo | Nov 7, 2017 | |
| D-VI | Stacey E. Plaskett | Nov 7, 2017 | |
| D-CA | Raul Ruiz | Dec 18, 2017 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred May 24, 2017 |
| Health Subcommittee | Referred May 26, 2017 |
Actions 3
Everything that happened, newest first.
- May 26, 2017Referred to the Subcommittee on Health.
- May 24, 2017Introduced in House
- May 24, 2017Referred to the House Committee on Energy and Commerce.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Constitutional authority
The sponsor’s statement, as printed in the Congressional Record, vol. 163, no. 90, May 24, 2017, page H4570.
Related bills 1
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| HR 5182 | Promoting Life-Saving New Therapies for Neonates Act of 2016 | Reintroduction of | May 13, 2016 |
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To promote the development of safe drugs for neonates.
- Short Titles as Introduced
- Promoting Life-Saving New Therapies for Neonates Act of 2017
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Administrative law and regulatory procedures
- Child health
- Congressional oversight
- Department of Health and Human Services
- Drug safety, medical device, and laboratory regulation
- Drug therapy
- Food and Drug Administration (FDA)
- Government studies and investigations
- Health
- Health promotion and preventive care
- Medical research
Text 1
Each version as it was printed, newest first.
- May 24, 2017Introduced in House
Support LegiList
This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.